CLSD

Clearside Biomedical, Inc. [CLSD] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

CLSD Stock Summary

Top 10 Correlated ETFs

CLSD

Top 10 Correlated Stocks

CLSD

In the News

CLSD Financial details

Company Rating
-
Market Cap
93.4M
Income
-36.33M
Revenue
8.23M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
30
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-2.18
Forward P/E
-
PEG
-7.14
P/S
39.8
P/B
-6.8
P/C
-
P/FCF
-3.39
Quick Ratio
5.09
Current Ratio
5.28
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.59
EPS next Y
-
EPS next Q
-
EPS this Y
-7.02%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-7.9%
Revenue last 5Y
30.5%
Revenue Q/Q
638.65%
EPS Q/Q
-48.4%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-116%
ROE
3551%
ROC
-1.05%
Gross Margin
75%
Oper. Margin
-1357%
Profit Margin
-1813%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.65-2.12
52W High
-
52W Low
-
RSI
50
Rel Volume
0.18
Avg Volume
362.29K
Volume
64.71K
Perf Week
11.29%
Perf Month
-12.35%
Perf Quarter
-18.03%
Perf Half Y
-19.52%
-
-
-
-
Beta
2.326
-
-
Volatility
0.02%, 0.08%
Prev Close
4.83%
Price
0.8853
Change
5.39%

Something similar

Top by Market Cap
GOOGL
FXAIX
JPM
VFINX
MSF.DE
Top Correlated ETFs
ZCB.TO
SYLD.TO
ZBBB.TO
HMMJ.TO
ZQB.TO
Top Correlated Stocks
HQI
NTRB
RMAX
RILYL
7718.T
Similar Market Cap
RJA
BYSI
EVY
NRO
BMAQU

Company Profile

Healthcare Biotechnology
  • Volume Average 362.29K
  • Market Capitalization 93.4M
  • Employee 30
  • CEO Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D.
  • Headquarters Alpharetta,GA,US
  • IPO Date 2016-06-02
  • Website https://www.clearsidebio.com

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.